Expression of cathepsin E in pancreas: a possible tumor marker for pancreas, a preliminary report. Int. J. Cancer. 67:492.Azuma T, Hirai M, Ito S, Yamamoto K, Taggart RT, Matsuba T, Yasukawa K, Uno K, Hayakumo T and Nakajima M: Expression of cathepsin E in pancreas: A possibl...
Glial fibrillary acidic protein (GFAP) is a well-established marker for astrocytoma. As it is typically expressed in mature astrocytes, GFAP has been historically used to identify early-stage gliomas that are at a more-differentiated state. Recent studies though, have shown that GFAP can also be...
important. Each tumor marker has a unique life span in the blood. To monitor a treatment's success, enough time must have passed for the initial marker to be cleared from the blood. Tests done too soon may be falsely elevated because the marker produced by the untreated cancer is still ...
The main use of CEA is as a tumor marker, especially with intestinal cancer. The most common cancers that elevate CEA are in thecolonandrectum. Others: cancer of the pancreas, stomach, breast, lung, and certain types ofthyroidand ovarian cancer. Levels over 20 ng/ml before therapy are ass...
which have the potential to identify a preferred tumor marker for pancreatic adenocarcinoma. This review further elaborates on important genetic changes associated with the development and progression of pancreatic cancer that holds the key for the identification of a sensitive biomarker and which could ...
There is no ideal tumor marker as an early diagnosis and test for pancreatic cancer. a. CA19-9 It is one of the most widely used glycoprotein antigens. It is also the preferred marker for pancreatic cancer, with high sensitivity and specificity, but less sensitivity of 10–30% to early ...
A tumor marker in a biomedical setting can be defined as “a biological object present in human tissue and/or body fluids that is capable to differentiate between normal and abnormal biological conditions.” The National Institutes of Health added that i
CEA is a sign of colorectal, breast, lung, prostate, pancreas, and ovarian cancer. Prostate-specific antigen is a prognostic marker of prostate cancer. This biomolecule is produced primarily in the prostate gland and secreted into the prostate ducts. The level of PSA in healthy makes is less ...
CXCL10 expression was correlated with the proportion of TICs. Conclusion: CXCL10 is a potential prognostic marker for PAAD and provide additional insights into the treatment of PAAD based on TME transformation. However, more independent experimentation with the CXCL10 is need....
Within each patient sample, highly variable genes were detected and used for principal component analysis (PCA). Cells were then clustered with the Seurat package68. Cell type was annotated using known marker genes34,35,69,70,71. Tumor cells were identified based on the inferred presence of ...